Q1 Earnings Estimate for IOVA Issued By HC Wainwright

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Iovance Biotherapeutics in a research report issued on Friday, February 28th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will post earnings of ($0.23) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $32.00 target price on the stock. The consensus estimate for Iovance Biotherapeutics' current full-year earnings is ($1.24) per share. HC Wainwright also issued estimates for Iovance Biotherapeutics' Q4 2025 earnings at ($0.13) EPS.

Other analysts also recently issued research reports about the company. The Goldman Sachs Group dropped their price target on Iovance Biotherapeutics from $22.00 to $19.00 and set a "buy" rating on the stock in a research note on Monday. Truist Financial reduced their price target on Iovance Biotherapeutics from $25.00 to $15.00 and set a "buy" rating for the company in a research report on Monday. Robert W. Baird lowered their price objective on shares of Iovance Biotherapeutics from $24.00 to $20.00 and set an "outperform" rating on the stock in a report on Friday, February 28th. Piper Sandler reduced their target price on shares of Iovance Biotherapeutics from $7.50 to $6.00 and set a "neutral" rating for the company in a report on Friday, February 28th. Finally, Chardan Capital decreased their target price on shares of Iovance Biotherapeutics from $34.00 to $30.00 and set a "buy" rating for the company in a research report on Monday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $20.25.

Remove Ads

Iovance Biotherapeutics Stock Down 7.4 %

IOVA traded down $0.30 during trading on Monday, hitting $3.75. The company had a trading volume of 9,838,724 shares, compared to its average volume of 10,130,597. The firm's 50-day moving average price is $6.00 and its 200 day moving average price is $8.43. The company has a market capitalization of $1.14 billion, a PE ratio of -2.52 and a beta of 0.53. Iovance Biotherapeutics has a one year low of $3.62 and a one year high of $17.55.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.26) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.26). Iovance Biotherapeutics had a negative net margin of 451.25% and a negative return on equity of 58.43%. The firm had revenue of $73.69 million for the quarter, compared to analyst estimates of $72.17 million.

Hedge Funds Weigh In On Iovance Biotherapeutics

A number of institutional investors have recently added to or reduced their stakes in IOVA. Creative Planning lifted its stake in Iovance Biotherapeutics by 2.6% in the third quarter. Creative Planning now owns 73,489 shares of the biotechnology company's stock valued at $690,000 after acquiring an additional 1,896 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Iovance Biotherapeutics by 31.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,978 shares of the biotechnology company's stock valued at $105,000 after purchasing an additional 2,624 shares during the period. Creative Financial Designs Inc. ADV lifted its stake in Iovance Biotherapeutics by 59.3% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 21,740 shares of the biotechnology company's stock valued at $204,000 after purchasing an additional 8,090 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in Iovance Biotherapeutics by 142.3% during the third quarter. Farther Finance Advisors LLC now owns 15,389 shares of the biotechnology company's stock worth $145,000 after purchasing an additional 9,037 shares during the period. Finally, Beacon Financial Advisory LLC increased its position in Iovance Biotherapeutics by 42.7% during the third quarter. Beacon Financial Advisory LLC now owns 21,120 shares of the biotechnology company's stock worth $198,000 after buying an additional 6,320 shares during the last quarter. 77.03% of the stock is currently owned by institutional investors and hedge funds.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.